| 研究課題/領域番号 |
19K16512
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分48040:医化学関連
|
|---|
| 研究機関 | 東北大学 |
|---|
研究代表者 |
Baird Liam 東北大学, 医学系研究科, 助教 (90724914)
|
|---|
| 研究期間 (年度) |
2019-04-01 – 2021-03-31
|
| 研究課題ステータス |
完了 (2020年度)
|
| 配分額 *注記 |
4,290千円 (直接経費: 3,300千円、間接経費: 990千円)
2020年度: 2,210千円 (直接経費: 1,700千円、間接経費: 510千円)
2019年度: 2,080千円 (直接経費: 1,600千円、間接経費: 480千円)
|
|---|
| キーワード | Keap1-Nrf2 / synthetic lethal / Keap1 / Nrf2 |
|---|
| 研究開始時の研究の概要 |
Mutations in the Keap1-Nrf2 pathway are common events in human cancers, however there are currently no specific treatment options for tumors with activated Nrf2 signaling. Therefore, the purpose of this research is to identify compounds which function to specifically kill Nrf2-dependent tumors.
|
| 研究成果の概要 |
I developed a novel assay to identify compounds which could selectively kill tumour cells with high levels of NRF2. Thus, I identified two different classes of compounds, geldanamycin-derived HSP90 inhibitors, and the DNA damaging agent mitomycin C, which both displayed NRF2-dependent toxicity.
|
| 研究成果の学術的意義や社会的意義 |
As there are no approved drugs which can be used to treat patients with NRF2-dependent tumours, there is an urgent unmet clinical need to identify such drugs. In this project, I identified the chemotherapy drug mitomycin C to be an ideal candidate for drug repositioning to NRF2-dependent tumours.
|
